Veralox Therapeutics secures an option to acquire Nudge Therapeutics, adding preclinical cGAS inhibitors to its portfolio. The acquisition complements Veralox’s focus on inflammatory conditions and ...
A potent and selective inhibitor of 12-LOX, VLX-1005 inhibits platelet 12 ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites ...